KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella Pneumoniae ST307 Clinical Isolate

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2021 Oct 4

PMID 34606331

Citations 13

Authors

Agnes B Jousset

Saoussen Oueslati

Cecile Emeraud

Remy A Bonnin

Laurent Dortet

Bogdan I Iorga

Thierry Naas

Affiliations

Soon will be listed here.

Abstract

Resistance to the ceftazidime (CAZ)-avibactam (AVI) combination is increasingly being reported. Here, we report a CAZ-AVI-resistant Klebsiella pneumoniae strain belonging to the high-risk sequence type 307 (ST307) clone and producing Klebsiella pneumoniae carbapenemase 39 (KPC-39), a single-amino-acid variant of KPC-3 (A172T). Cloning experiments, steady-state kinetic parameters, and molecular dynamics simulations revealed a loss of carbapenemase activity and increased affinity for CAZ. KPC-39 was identified in a patient without prior exposure to CAZ-AVI, suggesting silent dissemination in European health care settings.

Citing Articles

Characteristic of KPC-12, a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in the Carbapenem-Resistant ST11-KL47 Clone Background.

Han W, Zhou P, Chen C, Wu C, Shen L, Wan C Infect Drug Resist. 2024; 17:2541-2554.

PMID: 38933778 PMC: 11199322. DOI: 10.2147/IDR.S465699.

Outbreak of NDM-5-producing ST307: an emerging high-risk antimicrobial resistance clone in Shanghai, China.

Zhu J, Wang G, Li M mSystems. 2024; 9(4):e0136923.

PMID: 38506533 PMC: 11019902. DOI: 10.1128/msystems.01369-23.

carbapenemase variants: the new threat to global public health.

Ding L, Shen S, Chen J, Tian Z, Shi Q, Han R Clin Microbiol Rev. 2023; 36(4):e0000823.

PMID: 37937997 PMC: 10732083. DOI: 10.1128/cmr.00008-23.

Emergence of KPC-134, a KPC-2 variant associated with ceftazidime-avibactam resistance in a ST11 clinical strain.

Huang X, Shen S, Chang F, Liu X, Yue J, Xie N Microbiol Spectr. 2023; :e0072523.

PMID: 37772834 PMC: 10580995. DOI: 10.1128/spectrum.00725-23.

Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant Carbapenemase-Producing Infections: A Retrospective, Observational, 2-Center Clinical Study.

Oliva A, Campogiani L, Savelloni G, Vitale P, Lodi A, Sacco F Open Forum Infect Dis. 2023; 10(7):ofad327.

PMID: 37476077 PMC: 10354859. DOI: 10.1093/ofid/ofad327.

References

Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A . Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018; 31(2). PMC: 5967687. DOI: 10.1128/CMR.00079-17. View

Djamdjian L, Naas T, Tande D, Cuzon G, Hanrotel-Saliou C, Nordmann P . CTX-M-93, a CTX-M variant lacking penicillin hydrolytic activity. Antimicrob Agents Chemother. 2011; 55(5):1861-6. PMC: 3088237. DOI: 10.1128/AAC.01656-10. View

Peirano G, Chen L, Kreiswirth B, Pitout J . Emerging Antimicrobial-Resistant High-Risk Klebsiella pneumoniae Clones ST307 and ST147. Antimicrob Agents Chemother. 2020; 64(10). PMC: 7508593. DOI: 10.1128/AAC.01148-20. View

Wong J, Romano M, Kerry L, Kwong H, Low W, Brett S . OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo. Nat Commun. 2019; 10(1):3957. PMC: 6718652. DOI: 10.1038/s41467-019-11756-y. View

Coppi M, Di Pilato V, Monaco F, Giani T, Conaldi P, Rossolini G . Ceftazidime-Avibactam Resistance Associated with Increased Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 . Antimicrob Agents Chemother. 2020; 64(4). PMC: 7179273. DOI: 10.1128/AAC.01816-19. View

Nelson K, Hemarajata P, Sun D, Rubio-Aparicio D, Tsivkovski R, Yang S . Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity. Antimicrob Agents Chemother. 2017; 61(10). PMC: 5610495. DOI: 10.1128/AAC.00989-17. View

Winkler M, Papp-Wallace K, Bonomo R . Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop. J Antimicrob Chemother. 2015; 70(8):2279-86. PMC: 4500773. DOI: 10.1093/jac/dkv094. View

Di Pilato V, Aiezza N, Viaggi V, Antonelli A, Principe L, Giani T . KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam. Antimicrob Agents Chemother. 2020; 65(1). PMC: 7927837. DOI: 10.1128/AAC.01429-20. View

Oueslati S, Iorga B, Tlili L, Exilie C, Zavala A, Dortet L . Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. J Antimicrob Chemother. 2019; 74(8):2239-2246. DOI: 10.1093/jac/dkz209. View

10.

Dabos L, Zavala A, Bonnin R, Beckstein O, Retailleau P, Iorga B . Substrate Specificity of OXA-48 after β5-β6 Loop Replacement. ACS Infect Dis. 2020; 6(5):1032-1043. DOI: 10.1021/acsinfecdis.9b00452. View

11.

Compain F, Dorchene D, Arthur M . Combination of Amino Acid Substitutions Leading to CTX-M-15-Mediated Resistance to the Ceftazidime-Avibactam Combination. Antimicrob Agents Chemother. 2018; 62(9). PMC: 6125495. DOI: 10.1128/AAC.00357-18. View

12.

Antonelli A, Giani T, Di Pilato V, Riccobono E, Perriello G, Mencacci A . KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. J Antimicrob Chemother. 2019; 74(8):2464-2466. DOI: 10.1093/jac/dkz156. View

13.

Mueller L, Masseron A, ProdHom G, Galperine T, Greub G, Poirel L . Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity. Antimicrob Agents Chemother. 2019; 63(12). PMC: 6879233. DOI: 10.1128/AAC.01111-19. View

14.

Naas T, Oueslati S, Bonnin R, Dabos M, Zavala A, Dortet L . Beta-lactamase database (BLDB) - structure and function. J Enzyme Inhib Med Chem. 2017; 32(1):917-919. PMC: 6445328. DOI: 10.1080/14756366.2017.1344235. View

15.

Shields R, Nguyen M, Press E, Chen L, Kreiswirth B, Clancy C . Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Carbapenemase-Producing : A Case Report and Review of Literature. Open Forum Infect Dis. 2017; 4(3):ofx101. PMC: 5493938. DOI: 10.1093/ofid/ofx101. View

16.

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

17.

Barnes M, Winkler M, Taracila M, Page M, Desarbre E, Kreiswirth B . Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering. mBio. 2017; 8(5). PMC: 5666153. DOI: 10.1128/mBio.00528-17. View

18.

Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R . GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013; 29(7):845-54. PMC: 3605599. DOI: 10.1093/bioinformatics/btt055. View

19.

Oueslati S, Tlili L, Exilie C, Bernabeu S, Iorga B, Bonnin R . Different phenotypic expression of KPC β-lactamase variants and challenges in their detection. J Antimicrob Chemother. 2019; 75(3):769-771. DOI: 10.1093/jac/dkz508. View

20.

Bonomo R, Burd E, Conly J, Limbago B, Poirel L, Segre J . Carbapenemase-Producing Organisms: A Global Scourge. Clin Infect Dis. 2017; 66(8):1290-1297. PMC: 5884739. DOI: 10.1093/cid/cix893. View